Abstract
Cardiac sodium channels are established therapeutic targets for the management of inherited and acquired arrhythmias by class I anti-arrhythmic drugs (AADs). These drugs share a common target receptor bearing two highly conserved aromatic side chains, and are subdivided by the Vaughan-Williams classification system into classes Ia-c based on their distinct effects on the electrocardiogram. How can these drugs elicit distinct effects on the cardiac action potential by binding to a common receptor? Here we use fluorinated phenylalanine derivatives to test whether the electronegative surface potential of aromatic side chains contributes to inhibition by six class I AADs. Surprisingly, we find that class Ib AADs bind via a strong electrostatic cationĝ€"pi interaction, whereas class Ia and Ic AADs rely significantly less on this interaction. Our data shed new light on drug-target interactions underlying the inhibition of cardiac sodium channels by clinically relevant drugs and provide information for the directed design of AADs.
Original language | English |
---|---|
Journal | Nature Communications |
Volume | 2 |
Pages (from-to) | 351 |
ISSN | 2041-1723 |
DOIs | |
Publication status | Published - 2011 |
Keywords
- Anti-Arrhythmia Agents
- Arrhythmias, Cardiac
- Cations
- Electrophysiology
- Humans
- Models, Molecular
- Mutagenesis
- NAV1.5 Voltage-Gated Sodium Channel
- Patch-Clamp Techniques
- Phenylalanine
- Receptors, Drug
- Sodium Channel Blockers
- Sodium Channels
- Static Electricity